Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic CEO takes the helm amid investor speculation:

This article was originally published in Clinica

Executive Summary

Medtronic's president and COO, William Hawkins, today succeeds Arthur Collins as the company's CEO. Mr Hawkins takes the helm amid speculation over whether he can increase the company's stock price and build up investor confidence (see Clinica No 1247, p 7). Missed earnings estimates is among the problems faced by the company. On August 21, the company's shares ended down 2% in after-hours trading following the announcement of weaker than expected first quarter sales in the company's implantable heart-regulating devices. Other problems include delays in getting new products to market and the lengthy transformation of insulin pump company MiniMed into a strong performing subsidiary. If Mr Hawkins cannot address these problems, some analysts believe that Medtronic will risk becoming an acquisition target. In-depth analysis to follow.

You may also be interested in...

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Warning Letter Roundup & Recap – 8 April 2020

Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.

Expanding The Tent: Improving Trial Participation Among Under-Represented Patient Populations

The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts